The Buzz, Issue #2 is now available! Check out this month’s selection of new publications clinically relevant to Canadian allergists, immunologists and dermatologists.

~ hivecanada

The Buzz Issue #2, April edition, was sent to all HIVE members by email on Monday, March 29, and can be accessed online here. This edition covers:

  • The allergists’ perspective on anaphylaxis risk with SARS-CoV-2 vaccines
  • Emerging biologics for chronic spontaneous urticaria
  • Predictors of response and non-response in chronic spontaneous urticaria
  • Real-world analysis of omalizumab in chronic inducible urticaria
  • Quantifying peanut allergen thresholds in Canadian children and young adults

To view all issues of The Buzz, go to thehivecommunity.org/the-buzz